Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.7K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

750
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
750
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

493
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
493
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.0K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac myosin binding protein C correlate with cardiac troponin I during an exercise training program in patients with HFrEF.

ESC heart failure·2025
Same author

[Digitalization and clinical decision tools].

Herz·2024
Same author

The liver-heart axis in patients with severe obesity: The association between liver fibrosis and chronic myocardial injury may be explained by shared risk factors of cardiovascular disease.

Clinical biochemistry·2023
Same author

Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.

European heart journal. Cardiovascular pharmacotherapy·2023
Same author

N-terminal pro-B-type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study.

Clinical cardiology·2023
Same author

Pharmacological treatment of CVD.

European heart journal. Cardiovascular pharmacotherapy·2022

Related Experiment Video

Updated: Apr 25, 2026

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
07:40

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training

Published on: October 10, 2019

6.8K

Troponins in heart failure.

T Omland1, H Røsjø1, E Giannitsis2

  • 1Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|August 26, 2014
PubMed
Summary

Cardiac troponins (cardiac troponin I and T) show promise as biomarkers for heart failure diagnosis and prognosis. High-sensitivity assays reveal their presence in various conditions, aiding risk assessment.

Keywords:
Cardiovascular risk markerHeart failureTroponin

More Related Videos

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
09:23

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum

Published on: December 13, 2017

5.9K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K

Related Experiment Videos

Last Updated: Apr 25, 2026

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
07:40

Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training

Published on: October 10, 2019

6.8K
Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
09:23

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum

Published on: December 13, 2017

5.9K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Heart failure signs and symptoms are often nonspecific and correlate poorly with objective cardiac function assessments.
  • Existing diagnostic tools like echocardiography have limitations in reflecting symptomatic status and functional capacity.
  • There is a critical need for reliable circulating biomarkers to enhance heart failure diagnosis and prognosis.

Purpose of the Study:

  • To review the clinical performance and utility of cardiac troponin measurements in heart failure.
  • To evaluate cardiac troponins as diagnostic and prognostic tools in symptomatic and asymptomatic left ventricular dysfunction.
  • To assess the role of cardiac troponins in high-risk phenotypes for developing heart failure.

Main Methods:

  • Review of current literature on cardiac troponin I and T assays.
  • Analysis of high-sensitivity assays for detecting low circulating concentrations of cardiac troponins.
  • Evaluation of diagnostic and prognostic information provided by troponin measurements in various cardiac conditions.

Main Results:

  • High-sensitivity cardiac troponin assays improve diagnostic accuracy in acute coronary syndromes.
  • Cardiac troponins are frequently detected in chronic circulation across diverse cardiac and non-cardiac diseases, including heart failure.
  • Cardiac troponin I and T provide valuable prognostic information for future heart failure development and adverse events in established heart failure.

Conclusions:

  • Cardiac troponins are emerging as crucial biomarkers in heart failure management.
  • Troponin measurements offer incremental diagnostic and prognostic value beyond traditional assessments.
  • These biomarkers are useful in asymptomatic individuals with left ventricular dysfunction and those at high risk for heart failure.